NanoViricides and CDC Collaborate in Rabies Treatment Study
Posted on: Tuesday, 5 August 2008, 12:01 CDT
NanoViricides has signed a materials cooperative research and development agreement with the US Centers for Disease Control and Prevention in Atlanta, Georgia for rabies treatment study.
The study, to be performed in collaboration with the US Centers for Disease Control and Prevention (CDC) Rabies program, is scheduled to begin soon. This study will expand on two successful animal studies of RabiCide-I performed previously by the government of Vietnam.
Anil Diwan, president of NanoViricides, said: "Collaborating with CDC in designing and conducting these studies is an important step forward. If the current studies are successful, we anticipate that this will be instrumental in helping our anti-rabies nanoviricide towards drug approval and widespread use across the world."
Source: Datamonitor
Related Articles
- NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
- Vista Announces Paredones Amarillos Feasibility Study Results and Provides Update on Permitting Status for the Project
- Isolagen, Inc. Reports Positive Top-Line Results From Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and Are Statistically Significant
- Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data From Pivotal Study of LIALDA(TM) (Mesalamine) Presented at DDW
- Crucell Initiates Phase II Study of Rabies Combination Therapy in Philippines
- Pharmaceutical-Sponsored Studies Studied
- Study: Studies May Be Harmful to Your Mental Health
- Salix Announces Completion of First XIFAXAN(R) Travelers' Diarrhea Prevention Study; Study Results Highly Statistically Significant (P Less Than 0.0001)
- Downs Safety Behind Study ; Study: 4 Ways Ease Commuters' Way
- Getting Plant Genes To Glow
 |
 |
User Comments (0)
RSS Feeds